Pipeline
As of October 25, 2024
State of New Product Development［PDF: 255.2 KB］
- ・The information on this page is not intended to promote or advertise MTPC products, or to recommend off-label or unapproved use of any product.
- ・If the product is being developed in multiple countries, including the US, "Global" is indicated in "Region/Country".
- ・When "Region/Country" is "Global", the most advanced stage of development among all regions/countries is indicated.
- ・If the "Stage" is filed and after, "Region/Country" is, in principle, Japan, the US, Europe, China, and Asia (excluding Japan and China). And not all region/countries are listed.
Disease Area:
| Disease Area | Development code | Indications |
Stage
123Filed
|
Region / Country |
Central nervous system
MT-5199
Tardive dyskinesia
Asia
- Product name
- Dysval
- Generic name
- Valbenazine
- Mechanism(Indications)
- Vesicular monoamine transporter type 2 inhibitor(Tardive dyskinesia)
- Origin/licensee
- Licensed from Neurocrine Biosciences (US)
Central nervous system
MT-210
Schizophrenia
US
- Generic name
- Roluperidone
- Mechanism(Indications)
- 5-HT2A/Sigma 2 receptor antagonist(Schizophrenia)
- Origin/licensee
- Licensed to Minerva Neurosciences (US)
Central nervous system
MT-210
Schizophrenia
Europe
- Generic name
- Roluperidone
- Mechanism(Indications)
- 5-HT2A/Sigma 2 receptor antagonist(Schizophrenia)
- Origin/licensee
- Licensed to Minerva Neurosciences (US)
Central nervous system
ND0612
Parkinson's disease
Global
- Generic name
- Levodopa/Carbidopa
- Mechanism(Indications)
- Continuous SC pump(Parkinson's disease)
- Origin/licensee
- In-house
Central nervous system
MT-0551
Myasthenia gravis
Japan
- Product name
- Uplizna
- Generic name
- Inebilizumab
- Mechanism(Indications)
- Humanized anti-CD19 monoclonal antibody(Myasthenia gravis)
- Origin/licensee
- Licensed from Amgen (US) and co-developed
Central nervous system
MT-3921
Spinal cord injury
Global
- Generic name
- Unasnemab
- Mechanism(Indications)
- Anti-RGMa antibody(Spinal cord injury)
- Origin/licensee
- Co-discovered with Osaka University (Japan)
Central nervous system
MT-3921
HTLV-1 associated myelopathy
Japan
- Generic name
- Unasnemab
- Mechanism(Indications)
- Anti-RGMa antibody(HTLV-1 associated myelopathy)
- Origin/licensee
- Co-discovered with Osaka University (Japan)
Immuno-inflammation
MT-7117
Erythropoietic protoporphyria, X-Linked protoporphyria
Global
- Generic name
- Dersimelagon
- Mechanism(Indications)
- Selective melanocortin 1 receptor agonist(Erythropoietic protoporphyria, X-Linked protoporphyria)
- Origin/licensee
- In-house
Immuno-inflammation
MT-7117
Systemic sclerosis
Global
- Generic name
- Dersimelagon
- Mechanism(Indications)
- Selective melanocortin 1 receptor agonist(Systemic sclerosis)
- Origin/licensee
- In-house
Immuno-inflammation
MT-0551
IgG4-related disease
Japan
- Product name
- Uplizna
- Generic name
- Inebilizumab
- Mechanism(Indications)
- Humanized anti-CD19 monoclonal antibody(IgG4-related disease)
- Origin/licensee
- Licensed from Amgen (US) and co-developed
Immuno-inflammation
MT-0551
Systemic sclerosis
Japan
- Product name
- Uplizna
- Generic name
- Inebilizumab
- Mechanism(Indications)
- Humanized anti-CD19 monoclonal antibody(Systemic sclerosis)
- Origin/licensee
- Licensed from Amgen (US)
Immuno-inflammation
MT-2990
ANCA associated vasculitis
Japan
- Mechanism(Indications)
- Fully human anti-interleukin-33 (IL-33) monoclonal antibody(ANCA associated vasculitis)
- Origin/licensee
- In-house
Immuno-inflammation
MT-3534
Autoimmune disease
Japan
- Mechanism(Indications)
- Antibody(Autoimmune disease)
- Origin/licensee
- Co-discovered with Pharma Foods International (Japan)
Oncology
MT-2111
Relapsed/Refractory diffuse large B-cell lymphoma
Japan
- Generic name
- Loncastuximab tesirine
- Mechanism(Indications)
- Anti-CD19 antibody drug conjugate(Relapsed/Refractory diffuse large B-cell lymphoma)
- Origin/licensee
- Licensed from ADC Therapeutics (Switzerland)
Oncology
MT-2111
Relapsed/Refractory diffuse large B-cell lymphoma (with rituximab)
Japan
- Generic name
- Loncastuximab tesirine
- Mechanism(Indications)
- Anti-CD19 antibody drug conjugate(Relapsed/Refractory diffuse large B-cell lymphoma (with rituximab))
- Origin/licensee
- Licensed from ADC Therapeutics (Switzerland) and co-developed (Global study ongoing)
Others
MT-4580
Secondary hyperparathyroidism
Asia
- Product name
- Orkedia
- Generic name
- Evocalcet
- Mechanism(Indications)
- Ca sensing receptor agonist(Secondary hyperparathyroidism)
- Origin/licensee
- Licensed to Kyowa Kirin (Japan)
Others
MT-2765
Hypertension
China
- Mechanism(Indications)
- Renin inhibitor(Hypertension)
- Origin/licensee
- Licensed to Shanghai Pharmaceuticals (China)
There is no development status of the applicable area.
Please select one or more disease areas.